Methods and compositons for modulations of immune response
AssigneesLa Jolla Institute for Immunology, University of Southampton
InventorsPandurangan VIJAYANAND, Ferhat AY, Divya SINGH, Anusha Preethi GANESAN, Bharat PANWAR, Christian OTTENSMEIER
Life of this patent
Estimating the term…
Abstract
Disclosed herein are isolated follicular helper T cell (TFH) and engineered follicular helper T cell (TFH) and methods of isolating or engineering such cells. Further disclosed herein are methods of using such cells for treating diseases, such as cancer.
Claims25
An engineered T-follicular helper (Tfh)-like tumor-infiltrating cell engineered to modulate expression of the surface markers CD4, CXCL13 and CXCR5 or one or more proteins selected from MAF, SH2D1A (SAP), PDCD1, BTLA, CD200, and BCL6.
-9. (canceled)
An isolated T-follicular helper (Tfh)-like tumor-infiltrating cell expressing the surface markers CD4 and CXCL13 and lacking the surface marker CXCR5.
(canceled)
-55. (canceled)
A method of determining whether a subject will respond to a treatment for cancer comprising measuring the amount of one or more of:
- CD4+CXCL13+CXCR5− Tfh-like tumor-infiltrating cell, and/or CD4+CXCL13+CXCR5′GZMB+ cytotoxic Tfh-like tumor-infiltrating cell in a sample isolated from the subject, wherein higher amounts of the cells indicates that the subject is likely to respond to the treatment and lower amounts of the cells indicates that the subject is not likely to respond to the treatment.
-62. (canceled)
-70. (canceled)
Dependencies are inferred from the claim text.